Global Allogeneic cell therapies use the transfer of cells from a donor to patient. Stem cells collected from the donor whose tissue type closely matches that of the patient are predominantly used in allogenic cell therapies. There are various sources for to get allogenic cell among which blood taken from the placenta and umbilical cord of newborns is the prominent source of cells for allogeneic transplants. The small volume of blood comprises high number of cells that are eligible to multiply quickly.

Moreover, raising prevalence of chronic diseases and increasing funding for stem cell research start-ups are driving the growth of allogeneic stem cell therapy market. Currently number of companies are developing a wide range of tissue engineered products and allogeneic cell therapies aiming to bring about an era of regenerative medicine to treat people with unmet medical needs. Additionally, rise in prevalence of cancer and cardiovascular diseases is expected to boost the global allogeneic stem cell therapy market. For instance, JKastrup has ongoing Phase II clinical trial for allogeneic adipose tissue-derived stromal/stem cell therapy in patients with ischemic heart disease and heart failure.

The Global Allogeneic cell therapies market is segmented on the basis of cell type, cell/tissue source, indication, and region. Based on the cell type, the market is divided into cardiosphere-derived cells (CDCS), fibroblasts, t-cells, mesenchymal stem cells (MSCS), hematopoietic stem cells (HSCS) and others. on the basis of cell/tissue source, the market is segmented into skin, blood, PBC, BM and others. Based on the indication, the market is divided into acute graft-versus-host disease (gvhd), chronic ulcers and diabetic foot ulcers, osteoarthritis, crohn’s disease, cardiovascular disease, solid tumors/cancers and others (alzheimer’s disease, etc). Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.

The key players of this market include Atara Biotherapeutics, Artiva Biotherapeutic, Adaptimmune Therapeutics plc, Adicet Bio, Inc., Allogene Therapeutics, Athersys, Inc., BioCardia Inc., Bluebird Bio, BlueRock Therapeutics LP, Bone Therapeutics, Celyad, Capricor Therapeutics, Cellectis, Cyto Therapeutics Pty Limited, Cynata Therapeutics, Century Therapeutics, GammaDelta Therapeutics Limited, Fate Therapeutics, Osiris Therapeutics, Inc., Organogenesis Inc., Mesoblast Ltd, MEDIPOST, Nkarta, Inc., NantKwest, Pluristem Therapeutics Inc, Regeneus, Lineage Cell Therapeutics, Inc.,  Stempeutics, Stemedica Cell Technologies, Inc., TiGenix (Takeda) and TCR² Therapeutics.